Sofiya Latifyan - Concepedia

Author

Sofiya Latifyan

Also Known As

Fabrice Lalubin, Latifyan S, Latifyan Sofiya, Latifyan, Sofiya, S. Latifyan, Sofia Latifyan, Sofiya Bedo Latifyan, Sofiya Latifyan

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

University of Lausanne University Hospital of Lausanne

About

Sofiya Latifyan is an author at University of Lausanne specializing in tumor biology, immunology, and tumor immunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	36
2	Cell Biology	1	1	36
3	Immunology	1	1	36
4	Immunotherapy	1	1	36
5	Tumor Biology	1	1	36

Sofiya Latifyan

Publications

422

Citations

H-Index

Page 1

	Year	Citations
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy Eleonora Ghisoni, Alexandre Wicky, Hasna Bouchaab, European Journal of Cancer	2021	180
<sup>68</sup>Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis Sarah Boughdad, Sofiya Latifyan, Craig Fenwick, Journal for ImmunoTherapy of Cancer	2021	71
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany Julia Maria Ressler, Matthias Karasek, Lukas Koch, Journal for ImmunoTherapy of Cancer	2021	50
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma Johanna Chiffelle, David Barras, Rémy Pétremand, Immunity Radiation OncologyCancer ImmunosurveillanceT-regulatory CellMelanomaImmunology	2024	36
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events Alexander Coukos, Julien Vionnet, Michel Obéid, Journal for ImmunoTherapy of Cancer	2022	33
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series Alex Vicino, Andreas F. Hottinger, Sofiya Latifyan, Journal of Neurology	2023	17
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors André Manuel da Silva Lopes, Sara Colomer‐Lahiguera, Célia Darnac, Supportive Care in Cancer	2023	14
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy Douglas Daoudlarian, Amandine Ségot, Sofiya Latifyan, Annals of Oncology	2024	11
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma Victor Joo, Karim Abdelhamid, Alessandra Noto, Nature Communications	2024	10

Page 1